MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness
Margherita Puppo(Université Claude Bernard Lyon 1), Philippe Clézardin(Université Claude Bernard Lyon 1), Emmanuelle Charafe‐Jauffret(Inserm), Michele Iuliani(Campus Bio Medico University Hospital), Christophe Ginestier(Inserm), Julien Wicinski(Centre National de la Recherche Scientifique), Davide Ceresa(Ospedale Policlinico San Martino), Penelope D. Ottewell(University of Sheffield), Manoj K. Valluru(University of Sheffield), Martine Croset(Université Claude Bernard Lyon 1), Ashrin Khan(University of Sheffield), Francesco Pantano(Università Campus Bio-Medico)
Cited by 8
Related Papers
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
|Journal of Clinical Investigation|2010|738
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418
Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
|Clinical Cancer Research|2019|184